Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Update

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the target of a significant decrease in short interest in the month of July. As of July 15th, there was short interest totaling 49,784 shares, a decrease of 39.9% from the June 30th total of 82,827 shares. Approximately 1.1% of the company’s shares are sold short. Based on an average daily volume of 87,989 shares, the short-interest ratio is currently 0.6 days.

Sonoma Pharmaceuticals Price Performance

NASDAQ SNOA traded up $0.01 during mid-day trading on Thursday, reaching $1.10. 2,053 shares of the stock were exchanged, compared to its average volume of 119,929. The stock has a market cap of $5.29 million, a P/E ratio of -0.58 and a beta of 1.27. Sonoma Pharmaceuticals has a one year low of $0.85 and a one year high of $6.92. The stock has a 50 day simple moving average of $1.16 and a 200-day simple moving average of $1.98.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last issued its quarterly earnings results on Tuesday, June 16th. The company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.09). Sonoma Pharmaceuticals had a negative return on equity of 43.95% and a negative net margin of 16.26%.The business had revenue of $5.56 million for the quarter, compared to analyst estimates of $5.57 million.

Institutional Trading of Sonoma Pharmaceuticals

An institutional investor recently raised its position in Sonoma Pharmaceuticals stock. DRW Securities LLC increased its stake in shares of Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) by 257.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 60,977 shares of the company’s stock after acquiring an additional 43,907 shares during the quarter. DRW Securities LLC owned approximately 3.59% of Sonoma Pharmaceuticals worth $222,000 at the end of the most recent quarter. Institutional investors own 1.95% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Sonoma Pharmaceuticals in a research report on Friday, July 24th. One analyst has rated the stock with a Sell rating, According to MarketBeat, Sonoma Pharmaceuticals currently has a consensus rating of “Sell”.

Sonoma Pharmaceuticals Company Profile

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.